A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

Inclusion Criteria: * Clinical diagnosis of nonsegmental vitiligo. * History of prior vitiligo treatment with a total duration of at least 3 months. * Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit. * Willingness to avoid pregnancy or fathering children * Further inclusion criteria apply. Exclusion Criteria: * Other forms of vitiligo (eg, segmental) or other skin depigmentation disorders. * Uncontrolled thyroid function at screening as determined by the investigator. * Women who are pregnant (or who are considering pregnancy) or lactating. * Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator. * Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis. * Participants known to be infected with HIV, Hepatitis B, or Hepatitis C. * Laboratory values outside of the protocol-defined ranges. * Further exclusion criteria apply.